Phase 1B and 1C Clinical trials of PP1420
Research type
Research Study
Full title
A double-Blind, Randomised, Placebo controlled Dose Escalation study to assess the safety, tolerability and efficacy of single and multiple doses of PP 1420 in healthy subjects
IRAS ID
147397
Contact name
Stephen Bloom
Contact email
Sponsor organisation
Joint Research Compliance Office, Imperial College London / Imperial College Healthcare NHS Trust
Eudract number
2014-001908-22
Research summary
When humans eat, the bowels naturally secrete chemicals into the blood stream which makes people feel full and hence stop eating. One of theses chemicals is known as PP. We have previously shown that injections of PP reduce appetite and food intake in human volunteers. We have now developed a long acting version of PP called PP1420 as a treatment for obesity. PP1420 has been tested in animals and has been shown to be safe and to reduce their appetite. PP1420 has been tested in humans for the first time in 2010 and has been shown to be safe and well tolerated. This study is a follow on study to test PP1420 over a higher dose range
REC name
London - West London & GTAC Research Ethics Committee
REC reference
14/LO/0824
Date of REC Opinion
3 Jul 2014
REC opinion
Further Information Favourable Opinion